PMID- 23514733
OWN - NLM
STAT- MEDLINE
DCOM- 20140317
LR  - 20221207
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 8
DP  - 2013 Aug
TI  - Double-blind, randomized study evaluating the glycemic and anti-inflammatory 
      effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients 
      with type 2 diabetes.
PG  - 2239-46
LID - 10.2337/dc12-1835 [doi]
AB  - OBJECTIVE: Inflammation is associated with pancreatic beta-cell apoptosis and 
      reduced insulin sensitivity. Literature suggests that interleukin (IL)-1beta may 
      contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study 
      aimed to determine the efficacy, safety, and tolerability of LY2189102, a 
      neutralizing IL-1beta antibody, in T2DM patients. RESEARCH DESIGN AND METHODS: Phase 
      II, randomized, double-blind, parallel, placebo-controlled study of subcutaneous 
      LY2189102 (0.6, 18, and 180 mg) administered weekly for 12 weeks in T2DM patients 
      on diet and exercise, with or without approved antidiabetic medications. RESULTS: 
      LY2189102 reduced HbA1c at 12 weeks (adjusted mean differences versus placebo: 
      -0.27, -0.38 and -0.25% for 0.6, 18 and 180 mg doses, respectively), and fasting 
      glucose at multiple time points compared with placebo. LY2189102 also reduced 
      postprandial glycemia, and inflammatory biomarkers, including hs-CRP and IL-6. 
      LY2189102 was generally well tolerated. CONCLUSIONS: Weekly subcutaneous 
      LY2189102 for 12 weeks was well tolerated, modestly reduced HbA1c and fasting 
      glucose, and demonstrated significant anti-inflammatory effects in T2DM patients. 
      Neutralizing IL-1beta holds promise as a convenient adjuvant treatment for T2DM.
FAU - Sloan-Lancaster, Joanne
AU  - Sloan-Lancaster J
AD  - 1Chorus, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana, 
      USA j.s.lancas@lilly.com
FAU - Abu-Raddad, Eyas
AU  - Abu-Raddad E
FAU - Polzer, John
AU  - Polzer J
FAU - Miller, Jeffrey W
AU  - Miller JW
FAU - Scherer, Joel C
AU  - Scherer JC
FAU - De Gaetano, Andrea
AU  - De Gaetano A
FAU - Berg, Jolene K
AU  - Berg JK
FAU - Landschulz, William H
AU  - Landschulz WH
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130320
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Interleukin-1beta)
RN  - 0 (LY2189102)
RN  - 0 (Placebos)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antibodies, Neutralizing/*therapeutic use
MH  - Blood Glucose/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Glycated Hemoglobin/drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Interleukin-1beta/*immunology
MH  - Male
MH  - Middle Aged
MH  - Placebos
PMC - PMC3714510
EDAT- 2013/03/22 06:00
MHDA- 2014/03/19 06:00
PMCR- 2014/08/01
CRDT- 2013/03/22 06:00
PHST- 2013/03/22 06:00 [entrez]
PHST- 2013/03/22 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - dc12-1835 [pii]
AID - 1835 [pii]
AID - 10.2337/dc12-1835 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Aug;36(8):2239-46. doi: 10.2337/dc12-1835. Epub 2013 Mar 20.